Abstract 473P
Background
Surgical resection (R) ± adjuvant (adj) chemotherapy (CT) is recommended for patients (pts) with stage II–IIIA NSCLC and select pts with stage IB NSCLC, however, 5-yr overall survival rates are suboptimal. ADAURA showed a survival benefit with adj osimertinib after surgery ± adj CT in pts with resected stage IB–IIIA EGFR-mutation positive (EGFRm) NSCLC; this tx is now standard of care in this setting. EGFRm NSCLC is prevalent in China; we report the proportion of pts with EGFRm NSCLC, pt demographics and tx patterns from a Chinese cohort of a global retrospective rw study prior to adj osimertinib approval.
Methods
The study population included pts ≥18 yr old, with stage IA–IIIA NSCLC who had a test for EGFR mutations (EGFRmut) and were diagnosed 01 Jan 2015–31 Dec 2020. Primary objective assessed in these pts: proportion of EGFRm NSCLC. Pts diagnosed 01 Jan 2015–31 Dec 2017, who had complete surgical R, were assessed for pt characteristics and tx patterns (primary objectives) and sites of recurrence (secondary objective) from diagnosis until 31 Dec 2020 or last follow-up/death.
Results
Of 4,636 pts, 2,248 (48%) had EGFRm NSCLC, of whom 83% had common EGFRmut; proportion of common EGFRmut did not differ by age/NSCLC stage. Proportion of EGFRm NSCLC was similar in a subgroup of 300 pts who had R (149 [50%], 85% common EGFRmut). In pts who had R, mean age was 58 yr (range 31–81), 50% were female, 65% never smokers; open lobectomy (53%) and video-assisted thoracoscopic surgery (29%) were the most common first R procedures; 56% of pts did not receive systemic tx (Table). In pts who had R, 121 (40%) had recurrence, of whom 83% had distant recurrence; most common sites of recurrence: lung (45%), bone (17%), brain (13%) and pleura (10%). Table: 473P
Treatment received, n (%) | Patients who had resection n=300 | Disease stage | ||||
IA n=131 | IB n=60 | IIA n=28 | IIB n=18 | IIIA n=63 | ||
Surgery only | 169 (56) | 112 (85) | 29 (48) | 6 (21) | 6 (33) | 16 (25) |
Surgery + (neo)adjuvant treatment* | 131 (44) | 19 (15) | 31 (52) | 22 (79) | 12 (67) | 47 (75) |
Neoadjuvant treatment + surgery + adjuvant treatment | 4 (1) | 0 | 0 | 1 (4) | 0 | 3 (5) |
Surgery + adjuvant treatment | 127 (42) | 19 (15) | 31 (52) | 21 (75) | 12 (67) | 44 (70) |
*No patients received neoadjuvant treatment only
Conclusions
Around half of Chinese pts with stage IA–IIIA NSCLC in this study had EGFRm NSCLC. Of pts who had R, the majority did not receive systemic tx; these data highlight the need for early-stage EGFR testing to optimise tx choice.
Clinical trial identification
Editorial acknowledgement
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Alice Walter, BSc, of Ashfield MedComms, an Inizio company, and was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
H. Wang: Non-Financial Interests, Personal, Local PI: AstraZeneca. S. Lu: Financial Interests, Personal, Research Funding: AstraZeneca, Hutchison, BMS, Heng Rui, BeiGene, Roche, Hansoh, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Roche, Hansoh; Financial Interests, Personal, Advisory Board: Hengrui Therapeutics; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Roche. Y. Li: Non-Financial Interests, Personal, Local PI: AstraZeneca. G. Hu: Non-Financial Interests, Personal, Local PI: AstraZeneca. Q. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. S. Tan: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract